MEI Pharma Inc (NASDAQ:MEIP) is trading in a very narrow range in early session on Thursday. The stock has been witnessing a weak trend since over the past month with a fall of around 7%.
Major Trigger:
MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program
Key Highlights:
- announced clinical data from a Phase 1b study of zandelisib, an investigational selective phosphatidylinositol 3-kinase delta (“PI3K”) inhibitor in clinical development for the treatment of B-cell malignancies, and the trial design of COASTAL, a Phase 3 study of zandelisib in combination with rituximab, will be highlighted in poster presentations at the 16th International Conference on Malignant Lymphoma (16-ICML) to be held June 18 – 22, 2021.
Market Reaction
As of 11:11, MEIP stock down by 0.16% to $3.15 with more than 82K shares traded hands, compared to its average volume of 652K shares. The stock has moved within a range of $3.1150 – 3.1900 after opening the trade at $3.19.
Technical Indicators
| Symbol | Value | Result | Symbol | Value | Result |
| ADX | 14.3444 | Neutral | ATR14 | 0.1830 | |
| CCI20 | 126.7273 | Buy | Chaikin Money Flow | -0.1512 | Sell |
| MACD | -0.0445 | Sell | Money Flow Index | 75.6859 | Buy |
| ROC | 8.9655 | Buy | RSI | 53.9884 | Buy |
| STOCH (14,3) | 90.1961 | OverBought | STOCH RSI | 1.0000 | OverBought |
| UO | 61.3673 | Buy | Williams %R | -9.8039 | OverBought |
){kind=link}